Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SGRY Stock Summary
Top 10 Correlated ETFs
SGRY
In the News
Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?
Surgery Partners (SGRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Surgery Partners (SGRY) Could Rally 39.04%: Here's is How to Trade
The mean of analysts' price targets for Surgery Partners (SGRY) points to a 39% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Warren Buffett's Annual Letter: Key Insights for Investors
Follow Warren Buffett's latest tips and bet on top-ranked stocks like Microsoft (MSFT), Amazon.com (AMZN), Surgery Partners (SGRY) and Nvidia (NVDA).
Here's What Key Metrics Tell Us About Surgery Partners (SGRY) Q4 Earnings
While the top- and bottom-line numbers for Surgery Partners (SGRY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Surgery Partners (SGRY) Beats Q4 Earnings Estimates
Surgery Partners (SGRY) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.27 per share a year ago.
Gear Up for Surgery Partners (SGRY) Q4 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Surgery Partners (SGRY) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Surgery Partners, Inc. Announces Fourth Quarter 2023 Earnings Release Date and Conference Call Details
BRENTWOOD, Tenn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its fourth quarter 2023 results before the market opens on Monday, February 26, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time)
Why Surgery Partners (SGRY) is Poised to Beat Earnings Estimates Again
Surgery Partners (SGRY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Surgery Partners feeling no pinch from macroeconomic weakness
Surgery Partners Inc. NASDAQ: SGRY is a leading healthcare services provider that owns and operates over 180 outpatient surgical centers in 31 states. Its integrated delivery model includes surgical facilities and ancillary services comprised of anesthesia services and multi-specialty physician groups.
Surgery Partners, Inc. to Present at Upcoming Investor Conference
BRENTWOOD, Tenn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced that Eric Evans, Chief Executive Officer and Dave Doherty, Chief Financial Officer will meet with investors at the J.P. Morgan Healthcare Conference, including a presentation on Monday, January 8, 2024 at 5:15p.m. (Eastern Time).
SGRY Financial details
SGRY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 37.93 | 38.14 | 30.72 | 27.62 | 21.84 | |
Net income per share | 0.95 | 0.03 | 0.98 | 0.95 | -0.09 | |
Operating cash flow per share | 2.68 | 5.06 | 1.2 | 1.73 | 2.34 | |
Free cash flow per share | 1.16 | 4.18 | 0.41 | 0.85 | 1.63 | |
Cash per share | 1.92 | 6.52 | 5.38 | 3.08 | 1.56 | |
Book value per share | 6.17 | 2.37 | 15.04 | 21.73 | 15.82 | |
Tangible book value per share | -71.45 | -72.06 | -54.61 | -45.45 | -8.11 | |
Share holders equity per share | 6.17 | 2.37 | 15.04 | 21.73 | 15.82 | |
Interest debt per share | 63.79 | 69.68 | 48.54 | 34.42 | 18.88 | |
Market cap | 755.82M | 1.41B | 3.87B | 2.56B | 4.02B | |
Enterprise value | 3.56B | 4.29B | 6.77B | 5.21B | 6.88B | |
P/E ratio | 16.4 | 1.09K | 54.71 | 29.45 | -337.68 | |
Price to sales ratio | 0.41 | 0.76 | 1.74 | 1.01 | 1.46 | |
POCF ratio | 5.84 | 5.73 | 44.41 | 16.13 | 13.68 | |
PFCF ratio | 13.52 | 6.94 | 131.13 | 32.76 | 19.6 | |
P/B Ratio | 2.54 | 12.24 | 3.55 | 1.28 | 2.02 | |
PTB ratio | 2.54 | 12.24 | 3.55 | 1.28 | 2.02 | |
EV to sales | 1.95 | 2.31 | 3.04 | 2.05 | 2.51 | |
Enterprise value over EBITDA | 10.35 | 12.58 | 14.98 | 10.33 | 13.07 | |
EV to operating cash flow | 27.52 | 17.39 | 77.76 | 32.8 | 23.43 | |
EV to free cash flow | 63.76 | 21.05 | 229.59 | 66.61 | 33.58 | |
Earnings yield | 0.06 | 0 | 0.02 | 0.03 | 0 | |
Free cash flow yield | 0.07 | 0.14 | 0.01 | 0.03 | 0.05 | |
Debt to equity | 9.74 | 27.65 | 3.03 | 1.47 | 1.08 | |
Debt to assets | 0.58 | 0.59 | 0.54 | 0.44 | 0.31 | |
Net debt to EBITDA | 8.15 | 8.43 | 6.42 | 5.25 | 5.44 | |
Current ratio | 1.32 | 1.44 | 1.76 | 1.87 | 1.71 | |
Interest coverage | 1.32 | 1.22 | 1.37 | 1.47 | 1.79 | |
Income quality | 2.87 | 189.92 | 1.23 | 1.83 | -24.69 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0.07 | 0 | 0 | |
Sales general and administrative to revenue | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.69 | 0.65 | 0.65 | 0.63 | 0.62 | |
Capex to operating cash flow | -0.57 | -0.17 | -0.66 | -0.51 | -0.3 | |
Capex to revenue | -0.04 | -0.02 | -0.03 | -0.03 | -0.03 | |
Capex to depreciation | -0.96 | -0.45 | -0.58 | -0.7 | -0.75 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 11.51 | 1.19 | 18.17 | 21.51 | 5.81 | |
ROIC | 0.06 | 0 | 0.06 | 0.05 | 0.08 | |
Return on tangible assets | 0.03 | 0 | 0.03 | 0.03 | 0 | |
Graham Net | -96.49 | -98.01 | -74.21 | -65.48 | -24.19 | |
Working capital | 127.9M | 244.7M | 409.3M | 427.6M | 372M | |
Tangible asset value | -3.45B | -3.51B | -3.96B | -4.18B | -1.02B | |
Net current asset value | -4.49B | -4.61B | -5.17B | -5.76B | -2.76B | |
Invested capital | 9.74 | 27.65 | 3.03 | 1.47 | 1.08 | |
Average receivables | 317.27M | 354.55M | 406.2M | 443.25M | 484.95M | |
Average payables | 90M | 98.45M | 112.55M | 138.25M | 164.3M | |
Average inventory | 44.83M | 51.35M | 58.75M | 66.25M | 73.3M | |
Days sales outstanding | 65.15 | 75 | 70.57 | 65.59 | 68.34 | |
Days payables outstanding | 25.07 | 24.71 | 26.3 | 28.17 | 29.18 | |
Days of inventory on hand | 12.01 | 13.91 | 12.86 | 13.27 | 12.4 | |
Receivables turnover | 5.6 | 4.87 | 5.17 | 5.56 | 5.34 | |
Payables turnover | 14.56 | 14.77 | 13.88 | 12.96 | 12.51 | |
Inventory turnover | 30.4 | 26.25 | 28.37 | 27.51 | 29.44 | |
ROE | 0.15 | 0.01 | 0.06 | 0.04 | -0.01 | |
Capex per share | -1.52 | -0.88 | -0.8 | -0.88 | -0.71 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 7 | 5.35 | 5.31 | 5.5 | 5.85 | |
Net income per share | 0.23 | 0.01 | 0.15 | 0.29 | -0.01 | |
Operating cash flow per share | 0.07 | 0.6 | 0.41 | 0.85 | 0.5 | |
Free cash flow per share | -0.15 | 0.4 | 0.21 | 0.7 | 0.34 | |
Cash per share | 2.8 | 1.97 | 1.41 | 1.93 | 1.56 | |
Book value per share | 19.77 | 15.76 | 16.05 | 16.36 | 15.8 | |
Tangible book value per share | -41.35 | 15.1 | -12.86 | -35.11 | -8.1 | |
Share holders equity per share | 19.77 | 15.76 | 16.05 | 16.36 | 15.8 | |
Interest debt per share | 29.59 | 23.37 | 20.82 | 23.62 | 17.53 | |
Market cap | 2.82B | 4.29B | 5.66B | 3.58B | 4.02B | |
Enterprise value | 5.46B | 6.91B | 8.05B | 6.29B | 6.89B | |
P/E ratio | 30.21 | 894.07 | 74.82 | 24.95 | -1.01K | |
Price to sales ratio | 3.98 | 6.44 | 8.47 | 5.32 | 5.47 | |
POCF ratio | 391.1 | 57.6 | 108.56 | 34.26 | 64.27 | |
PFCF ratio | -181.67 | 85.49 | 215.06 | 41.81 | 94.01 | |
P/B Ratio | 1.41 | 2.19 | 2.8 | 1.79 | 2.02 | |
PTB ratio | 1.41 | 2.19 | 2.8 | 1.79 | 2.02 | |
EV to sales | 7.73 | 10.37 | 12.06 | 9.33 | 9.37 | |
Enterprise value over EBITDA | 32.17 | 65.11 | 63.52 | 528.6 | 39.89 | |
EV to operating cash flow | 758.71 | 92.73 | 154.48 | 60.14 | 110.05 | |
EV to free cash flow | -352.43 | 137.62 | 306.01 | 73.4 | 160.96 | |
Earnings yield | 0.01 | 0 | 0 | 0.01 | 0 | |
Free cash flow yield | -0.01 | 0.01 | 0 | 0.02 | 0.01 | |
Debt to equity | 1.47 | 1.46 | 1.27 | 1.47 | 1.08 | |
Debt to assets | 0.44 | 0.43 | 0.39 | 0.43 | 0.31 | |
Net debt to EBITDA | 15.59 | 24.67 | 18.88 | 227.5 | 16.59 | |
Current ratio | 1.87 | 1.83 | 1.77 | 1.75 | 1.71 | |
Interest coverage | 2.3 | 1.55 | 2.05 | -1.66 | 2.36 | |
Income quality | 0.31 | -2.85 | -5.92 | 18.03 | -62.6 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.04 | 0.05 | 0.05 | 0.16 | 0.03 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.63 | 0.64 | 0.65 | 0.63 | 0.62 | |
Capex to operating cash flow | -3.15 | -0.33 | -0.5 | -0.18 | -0.32 | |
Capex to revenue | -0.03 | -0.04 | -0.04 | -0.03 | -0.03 | |
Capex to depreciation | -0.77 | -0.72 | -1.06 | -0.65 | -0.64 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 10.13 | 1.85 | 7.37 | 10.39 | 1.68 | |
ROIC | 0.02 | -0.04 | 0.02 | 0.02 | 0.02 | |
Return on tangible assets | 0.01 | 0 | 0.01 | 0.01 | 0 | |
Graham Net | -59.57 | 1.17 | -27.01 | -50.3 | -24.16 | |
Working capital | 427.6M | 393.8M | 351.6M | 374.8M | 372M | |
Tangible asset value | -4.18B | 1.92B | -1.62B | -4.3B | -1.02B | |
Net current asset value | -5.76B | 393.8M | -3.14B | -5.9B | -2.76B | |
Invested capital | 1.47 | 1.46 | 1.27 | 1.47 | 1.08 | |
Average receivables | 439.3M | 454.6M | 451.4M | 456.35M | 488.2M | |
Average payables | 145M | 148M | 137.95M | 140.15M | 162.9M | |
Average inventory | 70M | 71.6M | 71.05M | 69.85M | 72.3M | |
Days sales outstanding | 58.08 | 61.18 | 60.65 | 61.79 | 62.86 | |
Days payables outstanding | 26.1 | 24.42 | 23.05 | 26.35 | 27.81 | |
Days of inventory on hand | 12.29 | 12.14 | 12.32 | 12.29 | 11.81 | |
Receivables turnover | 1.55 | 1.47 | 1.48 | 1.46 | 1.43 | |
Payables turnover | 3.45 | 3.69 | 3.9 | 3.42 | 3.24 | |
Inventory turnover | 7.32 | 7.41 | 7.3 | 7.32 | 7.62 | |
ROE | 0.01 | 0 | 0.01 | 0.02 | 0 | |
Capex per share | -0.22 | -0.2 | -0.21 | -0.15 | -0.16 |
SGRY Frequently Asked Questions
What is Surgery Partners, Inc. stock symbol ?
Surgery Partners, Inc. is a US stock , located in Brentwood of Tn and trading under the symbol SGRY
Is Surgery Partners, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $64. The lowest prediction is $64 and the highest is $64
What is SGRY stock prediction ?
What is Surgery Partners, Inc. stock quote today ?
Surgery Partners, Inc. stock price is $29.83 today.
Is Surgery Partners, Inc. stock public?
Yes, Surgery Partners, Inc. is a publicly traded company.